683 Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

683 Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-247,958	Closed	-$528K	–	166
2026 Q1	$528K	Hold	247,958	–	–	0.03%	178
2025 Q4	$603K	Buy	+247,958	New	+$878K	0.03%	181
2024 Q1	–	Sell	-70,379	Closed	-$198K	–	154
2023 Q4	$198K	Buy	+70,379	New	+$165K	0.02%	203

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

683 Capital Management's BDTX Position: Q2 2026 in Review

683 Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 247,958 shares — an estimated $528K sold.

683 Capital Management first reported a position in BDTX in Q4 2023 and held it in 3 quarters. The position peaked at $603K in Q4 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

683 Capital Management reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 247,958 Black Diamond Therapeutics shares in Q2 2026, an estimated $528K.
683 Capital Management first reported a position in Black Diamond Therapeutics in Q4 2023 and held it in 3 quarters.
683 Capital Management's Black Diamond Therapeutics position peaked at $603K in Q4 2025.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.